Evidence map›Paper›PMID 41544024›Full record

ArticleThe Journal of organic chemistry2026

Rearrangement of 5-Indolyl-3-pyrrolin-2-ones into Privileged 4-Indolyl-3-pyrrolin-2-ones Leads to Identification of Antiproliferative Compounds Active under Hypoxia.

Dmitrii A Aksenov, Connor Edvall, Shivendran Vytheswaran, Alexander V Aksenov, Puppala Sathish, Alesia S Akulova, Nicolai A Aksenov, Tatyana S Galushko, Tayyaba Hasan, Sanku Mallik and 2 more

Abstract read
In one paragraph

Article in The Journal of organic chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dmitrii A AksenovDepartment of Chemistry, North Caucasus Federal University, 1a Pushkin St., Stavropol 355009, Russian Federation.
Connor EdvallDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota 58105, United States.ORCID 0000-0002-1268-8055
Shivendran VytheswaranWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States.
Alexander V AksenovDepartment of Chemistry, North Caucasus Federal University, 1a Pushkin St., Stavropol 355009, Russian Federation.
Puppala SathishDepartment of Chemistry and Biochemistry, Texas State University, 601 University Dr., San Marcos, Texas 78666, United States.
Alesia S AkulovaDepartment of Chemistry, North Caucasus Federal University, 1a Pushkin St., Stavropol 355009, Russian Federation.
Nicolai A AksenovDepartment of Chemistry, North Caucasus Federal University, 1a Pushkin St., Stavropol 355009, Russian Federation.
Tatyana S GalushkoDepartment of Chemistry, North Caucasus Federal University, 1a Pushkin St., Stavropol 355009, Russian Federation.
Tayyaba HasanWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States.ORCID 0000-0003-0871-6057
Sanku MallikDepartment of Pharmaceutical Sciences, North Dakota State University, Fargo, North Dakota 58105, United States.
Mohammad A SaadWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, United States.ORCID 0000-0002-3337-2076
Alexander KornienkoDepartment of Chemistry and Biochemistry, Texas State University, 601 University Dr., San Marcos, Texas 78666, United States.ORCID 0000-0003-2041-7367

Funding

Small Molecule Enhancers of Photodynamic Therapy for Skin CancerP01CA084203 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Brian William Pogue · 2001 to 2026
$27.9M
UMass Boston-DF/HCC U54 Partnership (2 of 2)U54CA156734 · NCI · UNIVERSITY OF MASSACHUSETTS BOSTON · PI ADAN COLON-CARMONA, Jill A. Macoska · 2010 to 2026
$24.9M
Addressing Chemoresistance in Pancreatic and Ovarian Cancers: Photodynamic Priming and Repurposing of Tetracyclines using Targeted Photo-Activable Multi-Inhibitor LiposomeR01CA260340 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI HUANG, HUANG CHIAO · 2021 to 2025
$3.2M
Echogenic Polymersomes for Triggered Contents ReleaseR01GM114080 · NIGMS · NORTH DAKOTA STATE UNIVERSITY · PI MALLIK, SANKU, SARKAR, KAUSIK · 2015 to 2023
$2.6M
NCI NIH HHS P01 CA084203NCI NIH HHS R01 CA260340NCI NIH HHS U54 CA156734NIGMS NIH HHS R01 GM114080
6 · The paper itself

Abstract

Herein, we describe a synthetic route toward privileged 4-indolyl-3,5-diaryl-3-pyrrolin-2-ones based on a previously reported Friedel-Crafts reaction of 5-hydroxy-3,5-diaryl-3-pyrrolin-2-ones with indole. The intermediate 5-indolyl-3,5-diaryl-3-pyrrolin-2-ones are not isolated but further reacted under one-pot conditions, leading to the indole moiety migration from position C5 to position C4 of the 3-pyrrolin-2-one ring. The optimal reaction conditions found involved stirring with 2 equiv of aluminum chloride in 1,4-dioxane to complete the Friedel-Crafts step and then heating at 130 °C for 40 min in a microwave reactor to achieve the rearrangement step. Using the developed chemistry, a variety of compounds were prepared for biological testing, including those oxidized at C5 because 5-hydroxy-3-pyrrolin-2-ones have been reported to possess diverse biological properties as well. The synthesized compounds were tested for antiproliferative activities against MDA-MB-231 triple-negative breast cancer cells under normoxic and hypoxic conditions at a single concentration of 10 μM, and a number of compounds belonging to each of the series were identified to have noteworthy antiproliferative action under both normoxia and hypoxia. Several compounds from each series were further tested against ovarian cancer cells, and compounds from each series were capable of reducing cell viability of chemotherapy-resistant OVCAR-5 cells by as much as 75-80% at a concentration of 5 μM.

Indexed as

Antineoplastic AgentsIndolesPyrrolesPyrrolidinonesCell HypoxiaCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsIndolesPyrrolesPyrrolidinones

Identifiers

PMID41544024
PMCPMC12933247

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.